Glenmark closes DCP for generic Seretide Accuhaler in Nordic region

01 Dec 2017 Evaluate

Glenmark Pharmaceuticals Europe (Glenmark) has successfully closed the Decentralised Registration Procedure (DCP) for generic Seretide Accuhaler in the Nordic region, including Sweden, Denmark, Norway, Finland and Iceland. This will be Glenmark’s first inhaled Respiratory product approval in Europe, and re-enforces Glenmark’s commitment in the respiratory area. The commercialization of the product would depend on national approval as well as substitution and pricing approvals.

Glenmark had entered into a Strategic Development & Licensing Agreement with Celon Pharma S.A. (Celon) to develop and market a generic version of GlaxoSmithKline’s Seretide Accuhaler product - Fluticasone / Salmeterol dry powder Inhaler in Europe. This is the first approval from the deal, and marks the entry of Glenmark in the Respiratory Generic segment.

The Fluticasone / Salmeterol dry powder Inhaler is a combination product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Seretide marketed by GlaxoSmithKline is among the top 3 pharmaceutical brands in Europe with sales of $1.1 billion as per IMS.


Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×